The contract is awarded for products that bring improvement to the healthcare industry. Coloplast, a global medical device ...

In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in ...

Coloplast will release its H1 2025/26 Interim Report on May 12, 2026 and will host a second, ordinary conference call on the ...

According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below ...

Good morning to those of you here in the room, and also good morning to those of you joining us virtually today. On behalf of the Coloplast management team and on behalf of Investor Relations, I would ...

It's my pleasure to welcome you to this year's AGM. There is direct translation via the company's website. So welcome to you all, whether you are here or outside. First of all, let me introduce ...

Coloplast A/S engages in the developing, manufacture, and markets medical products. It operates through the following segments: Chronic Care, Voice and Respiratory Care, Interventional Urology, ...

Coloplast A/S (CSE: COLOb) has reduced its fiscal year 2025/26 guidance to 5-6% organic sales growth from approximately 7% previously, and approximately 5% curren ...

CEST In connection with the publication of Coloplast’s interim financial results for H1 2025/26, to be released same day around 07:30 CEST, Coloplast will host a conference call to present the ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.